DATA GRAPHICS | Data Byte
The changing direction of deal flow between China and the West
Chinese biopharmas still in-license more from Western companies than vice versa, but the gap is narrowing
June 20, 2023 10:39 PM UTC
Western biopharma companies are increasingly turning to China for innovation, with 2022 the biggest year yet in terms of the number of out-licensing deals from Chinese companies to Western companies.
In 2022, biopharmas in the Americas and Europe struck at least 30 deals to gain access to innovative products developed by Chinese biotechs, triple the number of such deals in 2017. In 2017-2019, the number of China-to-West deals per year ranged from 9-14; whereas the last three years had a range of 23-30...